Enfortumab vedotin-ejfv | Antibody-Drug Conjugate inhibitor

Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.

CAS No. 1346452-25-2

Click to purchase products related to Enfortumab vedotin-ejfv

Purity & Quality Control

Batch: Purity: 99.8% Protein concentration: 5.6mg/ml Endotoxin Level: ＜1EU/mg

99.8

Choose Selective Antibody-Drug Conjugate Inhibitors

Biological Activity

Description	Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.

References
[1] Halford Z, et al. Ann Pharmacother. 2021 Jun;55(6):772-782.

References

[1] Halford Z, et al. Ann Pharmacother. 2021 Jun;55(6):772-782.

Product Details

CAS No.	1346452-25-2
DAR	3.6
ADC antiody	Enfortumab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field